Given that 5-LOX activation is also required for lipoxin and resolvin biosynthesis, our results implicate cPLA2 and 5-LOX activities as important drivers for the increase of both pro-inflammatory and pro-resolving lipids observed in brains with AD. These observations still need to be validated in clinical trials. This evidence concerns the gene ALOX5 and Alzheimer disease.